Related Experiment Video
Updated: Mar 14, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring
Yan Li1, Yanmei Wang1, Kai Niu1
1Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Purpose:
Acquired resistance is a bottleneck that restricts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for lung cancer. Ginsenoside Rg3 is an antiangiogenic agent which can down-regulate the expressions of vascular endothelial growth factor (VEGF) and EGFR. Combination of EGFR-TKI and ginsenoside Rg3 may be a promising strategy to delay acquired resistance. This retrospective study explored the efficacy and safety of this combined regimen in patients with EGFR mutation and advanced non-small cell lung cancer (NSCLC).
Results:
By the deadline of March 31th 2016, the median follow-up period reached 22.9 months. The median PFS was significantly longer in group A than in group B (12.4 months vs 9.9 months, P = 0.017). In addition, ORR was significantly higher in group A than in group B (59.6% vs 41.7%, P = 0.049). The median OS in group A showed no extended tendency compared with that in group B (25.4 months vs 21.4 months, P = 0.258). No significant difference in side effects was found between the two groups.
Methods:
A total of 124 patients with advanced NSCLC and EGFR active mutation were collected and analyzed. All of them were treated with first-line EGFR-TKI and divided into two groups. In group A (n=52), patients were administered EGFR-TKI plus ginsenoside Rg3 at standard doses. In group B (n=72), patients received EGFR-TKI alone. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and side effects were analyzed.
Conclusions:
Ginsenoside Rg3 improves median PFS and ORR of first-line EGFR-TKI treatment in EGFR-mutant advanced NSCLC patients, thus providing a new regimen to delay acquired resistance of EGFR-TKI.
Insights
Ginsenoside Rg3 combined with EGFR-TKI significantly improved progression-free survival and objective response rates in advanced non-small cell lung cancer patients. This combination therapy offers a new strategy to overcome acquired resistance to EGFR-TKI treatment.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) is a major challenge in treating EGFR-mutant non-small cell lung cancer (NSCLC).
- Ginsenoside Rg3, an antiangiogenic agent, down-regulates vascular endothelial growth factor (VEGF) and EGFR expression.
- Combining EGFR-TKI with ginsenoside Rg3 may overcome treatment resistance.
Purpose of the Study:
- To investigate the efficacy and safety of combining EGFR-TKI with ginsenoside Rg3 in patients with advanced NSCLC and EGFR mutations.
- To evaluate the potential of this combination therapy in delaying acquired resistance.
Main Methods:
- A retrospective analysis of 124 patients with advanced NSCLC and EGFR mutations treated with first-line EGFR-TKI.
- Patients were divided into two groups: Group A (EGFR-TKI + ginsenoside Rg3) and Group B (EGFR-TKI alone).
- Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and side effects were analyzed.
Main Results:
- The median follow-up was 22.9 months.
- Median PFS was significantly longer in Group A (12.4 months) compared to Group B (9.9 months) (P=0.017).
- Objective response rate (ORR) was significantly higher in Group A (59.6%) versus Group B (41.7%) (P=0.049). Median OS and side effects showed no significant differences between groups.
Conclusions:
- Ginsenoside Rg3 significantly improves median PFS and ORR in EGFR-mutant advanced NSCLC patients receiving first-line EGFR-TKI.
- This combination regimen provides a novel strategy to delay acquired resistance to EGFR-TKI therapy.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
